GET DAILY SIGNALSTalphera (TLPH) Narrows Q3 Loss as NEPHRO CRRT Enrollment Nears Close
Key Takeaways
- Talphera reported a third-quarter 2026 net loss of $4.0 million, or $0.05 per share, narrowing from a $4.4 million loss, or $0.11 per share, a year earlier.
- The per-share loss came in ahead of Wall Street's consensus estimate, marking another quarter in the company's consistent record of beating expectations.
- Cash, cash equivalents, and investments stood at $14.2 million as of September 30, 2026, with roughly $16 million in conditional financing tranches still available.
- Management said the NEPHRO CRRT registrational study has surpassed 75% enrollment but has slowed, prompting a request to the FDA to close enrollment by December 31, 2026.
- The company raised its estimate of peak annual U.S. sales for nafamostat in CRRT to more than $200 million.
Why the Quarter Matters for Investors
Talphera (TLPH) is a clinical-stage specialty pharmaceutical company, so its quarterly report centers less on product revenue and more on clinical progress, cash runway, and regulatory momentum. The company's lead candidate, Niyad, is an investigational nafamostat-based regional anticoagulant for use during continuous renal replacement therapy (CRRT), a procedure that filters blood for critically ill patients in hospital intensive care units. With no product revenue yet, investors focus on whether the pivotal NEPHRO CRRT study can finish enrollment, unlock top-line data, and keep the company funded through a potential regulatory submission. I checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Prior quarters showed narrowing losses and steady, if slowing, trial progress, making this report a key checkpoint for the Niyad timeline.
Breaking Down the Reported Results
For the third quarter of 2026, Talphera (TLPH) reported a net loss attributable to common shareholders of $4.0 million, or $0.05 per basic and diluted share, compared with a net loss of $4.4 million, or $0.11 per share, in the third quarter of 2025. The result beat the analyst consensus estimate of a larger loss per share, continuing the company's streak of topping expectations.
Revenue was essentially zero, consistent with its pre-commercial stage. Total operating expenses rose to $4.14 million from $3.42 million a year earlier, driven by higher research and development (R&D) expenses of $2.19 million (up from $1.80 million) and selling, general and administrative (SG&A) expenses of $1.95 million (up from $1.62 million). Excluding non-cash stock-based compensation, cash operating expenses totaled $3.8 million, up from $3.3 million in the prior-year period, reflecting increased Niyad development work and pre-launch commercial preparation.
Cash, cash equivalents, and investments were $14.2 million at September 30, 2026. Management reiterated that this balance, combined with roughly $16 million in remaining conditional financing tranches, is expected to fund operations through a potential premarket approval (PMA) decision in 2027.
How the Market Reacted
Shares reacted positively after the report, with the stock moving higher in after-hours trading as investors focused on the clinical and regulatory updates rather than the headline loss. The narrower-than-expected loss provided a modest positive signal, but the larger drivers of sentiment were management's plan to request an early close to the NEPHRO CRRT study and the upwardly revised market opportunity. Still, sentiment heading into the print had been cautious: the stock had drifted lower since the prior quarter's report and sat near its 200-day moving average, reflecting concerns about enrollment speed and the company's shrinking cash balance. The updated FDA engagement and the raised peak-sales estimate helped address some of those concerns.
What to Watch Going Forward
The central question for Talphera (TLPH) going forward is whether the NEPHRO CRRT study can close enrollment on an accelerated basis. Management has requested an FDA "Sprint Meeting" and is seeking agreement to conclude enrollment by December 31, 2026, given that current enrollment already provides more than 80% statistical power for the primary endpoint. FDA feedback is anticipated before year-end.
Top-line data are expected roughly four to six weeks after enrollment closes, which would set up a potential readout in early 2027. That milestone also matters for financing: the two remaining conditional tranches, totaling approximately $16 million, are expected to close around the time of the top-line data release. Investors should therefore watch for clarity on the final patient count, the timing of data, and whether the tranches close as planned.
On the commercial side, the company raised its estimate of peak annual U.S. sales for nafamostat in CRRT to more than $200 million and continues to cite draft KDIGO (Kidney Disease: Improving Global Outcomes) guidelines as supportive. Key factors to monitor include final guideline language, spending discipline against a declining cash balance, and any updates on a potential PMA submission and commercialization strategy.
My Take on Research Tools
In my own analysis, I often rely on Tickeron’s AI Screener to quickly filter clinical-stage names against peers using technical patterns, fundamentals, and performance metrics. It provides a structured way to surface potential setups without manual effort across thousands of stocks. This has become a regular part of how I cross-check ideas in the biotech space before diving deeper into company-specific updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TLPH in -13.71% downward trend, falling for three consecutive days on November 13, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TLPH declined for three days, in 318 of 348 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLPH as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TLPH turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The Aroon Indicator for TLPH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TLPH's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +7.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLPH advanced for three days, in 179 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
TLPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. TLPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.783) is normal, around the industry mean (6.379). P/E Ratio (-4.565) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Best Health Insurance Stocks to Buy: Navigating the Future of Healthcare Financing
Week (November 4 - November 8) in Review: Financial Leaders
AI Trading Bots: Top 10 Day Traders, Signals Only, on November 12 , 2024
AI Trading Bots: Top Auto-Traders, Our Brokerage, on January 16, 2025
Top Social Networking Stocks
General Information
a developer of innovative therapies for the treatment of acute and breakthrough pain
Industry PharmaceuticalsGeneric